{"id":170,"date":"2023-02-05T16:36:56","date_gmt":"2023-02-05T15:36:56","guid":{"rendered":"http:\/\/localhost:8888\/progetti\/laramed\/?page_id=170"},"modified":"2025-04-16T16:58:52","modified_gmt":"2025-04-16T14:58:52","slug":"projects","status":"publish","type":"page","link":"https:\/\/web.infn.it\/LARAMED\/projects\/","title":{"rendered":"Projects"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n
Radionuclide<\/strong><\/td> Main application and project<\/strong><\/td><\/tr>
99m<\/sup>Tc<\/strong><\/td>Cover 80% of all imaging procedures worldwide. We have developed an  alternative (direct) supply route through hospital cyclotrons. APOTEMA & TECHN-OSP<\/a><\/td><\/tr>
67<\/sup>Cu<\/strong><\/td>Emerging radionuclides for Theranostic, also in combination with 61\/64<\/sup>Cu
 (new production routes). COME<\/a>, INTEFF_TOTEM<\/a>, CUPRUM_TTD<\/a> and SPES_MED<\/td><\/tr>
47<\/sup>Sc<\/strong><\/td>Emerging radionuclide for Theranostic, also in combination with 43\/44g<\/sup>Sc
 (new production routes). PASTA<\/a>, E_PLATE<\/a> , REMIX<\/a> and SPES_MED<\/td><\/tr>
52\/51<\/sup>Mn<\/strong><\/td>Allowing a molecular fusion of PET with MRI in combination  with stable paramagnetic Mn isotopes. METRICS<\/a> <\/td><\/tr>
155<\/sup>Tb<\/strong><\/td>Emerging radionuclide for Theranostic, also in combination with 149\/152\/161<\/sup>Tb. REMIX<\/a> , APHRODITE-155<\/a> and SPES_MED<\/td><\/tr>
R&D  on new High Power Target concepts and tailored  radiochemistry solutions<\/strong>. STARDIS<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Radionuclide  Main application and project 99mTc Cover 80% of all imaging procedures worldwide. We have developed an  alternative (direct) supply route through hospital cyclotrons. APOTEMA & TECHN-OSP 67Cu Emerging radionuclides for Theranostic, also in combination with 61\/64Cu (new production routes). COME, INTEFF_TOTEM, CUPRUM_TTD and SPES_MED 47Sc Emerging radionuclide for Theranostic, also in combination with 43\/44gSc (new production routes). PASTA, E_PLATE , REMIX and SPES_MED 52\/51Mn…<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_themeisle_gutenberg_block_has_review":false,"_kad_post_transparent":"disable","_kad_post_title":"hide","_kad_post_layout":"left","_kad_post_sidebar_id":"sidebar-primary","_kad_post_content_style":"unboxed","_kad_post_vertical_padding":"hide","_kad_post_feature":"hide","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-170","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages\/170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/comments?post=170"}],"version-history":[{"count":6,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages\/170\/revisions"}],"predecessor-version":[{"id":3170,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages\/170\/revisions\/3170"}],"wp:attachment":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/media?parent=170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}